PC
YMAB

Polar Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Polar Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$19.4M Hold
506,083
– – 0.14% 134
2020
Q2 		$21.9M Buy
506,083
+125,000
+33% +$4.73M 0.19% 127
2020
Q1 		$9.95M Buy
381,083
+136,083
+56% +$3.95M 0.11% 168
2019
Q4 		$7.66M Buy
245,000
+229,498
+1,480% +$6.79M 0.07% 212
2019
Q3 		$404K Buy
+15,502
New +$396K ﹤0.01% 271

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polar Capital's YMAB Position: Q3 2020 in Review

Polar Capital held its Y-mAbs Therapeutics (YMAB) position steady in Q3 2020 at 506,083 shares worth $19.4M. The position accounts for 0.14% of the portfolio, ranked #134.

Polar Capital first reported a position in YMAB in Q3 2019 and has held it in 5 quarters since. The position peaked at $21.9M in Q2 2020. 106 funds tracked by Wall St. Rank hold YMAB as of Q3 2020.

  • Polar Capital held 506,083 shares of Y-mAbs Therapeutics worth $19.4M as of Q3 2020.
  • Polar Capital left its Y-mAbs Therapeutics share count unchanged in Q3 2020.
  • Y-mAbs Therapeutics made up 0.14% of Polar Capital's portfolio in Q3 2020, its #134 holding.
  • Polar Capital first reported a position in Y-mAbs Therapeutics in Q3 2019 and has held it in 5 quarters since.
  • Polar Capital's Y-mAbs Therapeutics position peaked at $21.9M in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.